For more than a
decade, a pharmacist-run service at an Iowa hospital that tests patients for
penicillin sensitivity has faced ups and downs, but the hospital has ultimately
remained committed to the program.
The service, at Iowa Methodist Medical
Center, a 670-bed community-based teaching hospita
FDA on May 8 announced the approval of vorapaxar oral tablets, in conjunction with aspirin or clopidogrel, to reduce the risk of thrombotic cardiovascular events in patients with peripheral arterial disease or a history of myocardial infarction.
Vorapaxar, a protease-activated receptor-1 antagoni
Diagnostics company Alere Inc. today announced a class I recall of INRatio2 PT/INR Professional test strips (PDF) because of reports of the results differing greatly from those obtained by a central laboratory.
The company said it has received nine reports describing serious adverse events and INR
ASHP CEO Paul W. Abramowitz, Pharm.D., Sc.D. (Hon.), FASHP, has joined the American Nurses Foundation (ANF) Board of Trustees. ANF is the charitable and philanthropic arm of the American Nurses Association.
“Paul will bring a vital interprofessional perspective to our work to transform health
The American Society of Health-System Pharmacists (ASHP) is introducing a new set of targeted electronic practice resources for pharmacists. Each ASHP eReport offers concise, solution-oriented information addressing the wide range of challenges pharmacists face in daily practice.
The first se
Wisconsin took a significant first step toward provider status this month as Gov. Scott Walker signed legislation that allows pharmacists to take on patient care services.
Wisconsin Act 294 allows licensed pharmacists to perform patient care services delegated to them by a licensed physici
and Novartis on April 29 announced the approval of the tyrosine kinase inhibitor ceritinib for the treatment of advanced lung cancer.
According to the labeling (PDF) for ceritinib, the drug is indicated for the treatment of anaplastic lymphoma kinase-positive metastatic non-small-ce
April 1 called on the chief of FDA's drugs division to defend a proposal that
would allow makers of generic drugs to unilaterally update safety information
in their products' professional labeling.
Janet Woodcock, director of FDA's Center
for Drug Evaluation and Research, told member